As attched
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The board of Novyra Pharmachem Limited (formerly Bansisons Tea Industries Limited) approved unaudited financial results for the quarter and nine months ended December 31, 2025. The company reported zero revenue from operations in Q3 FY26, with only Rs. 2.22 lakhs of other income for the quarter and Rs. 4.80 lakhs for the nine-month period. It posted a net loss of Rs. 1.15 lakhs in Q3 and Rs. 1.82 lakhs for the nine months, compared to losses of Rs. 0.88 lakhs and Rs. 1.34 lakhs in the corresponding prior periods. Employee costs were negligible (Rs. 0.39 lakhs in Q3), and paid-up equity capital stands at Rs. 630 lakhs (face value Rs. 10). The statutory auditor (D G M S & Co.) issued an unmodified limited review report with no qualifications.
The company remains effectively non-operational with no core business revenue and continues to report losses, though the loss amount is small in absolute terms. Shareholders should note the name change to Novyra Pharmachem Limited, suggesting a possible pivot in business identity, but no material improvement in operations is evident from these numbers.